Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regenerx Biopharmaceuticals's enterprise value is $0.24 Mil.
Regenerx Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.36 Mil. Therefore, Regenerx Biopharmaceuticals's EV-to-EBITDA for today is -0.18.
The historical rank and industry rank for Regenerx Biopharmaceuticals's EV-to-EBITDA or its related term are showing as below:
RGRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.18 Med: 0 Max: 0
Current: -0.18
RGRX's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 13.8
vs RGRX: -0.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regenerx Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Regenerx Biopharmaceuticals's share price for today is $0.0007.
Regenerx Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.903.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGRX vs MYMX, RGMP, NBRVF: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Regenerx Biopharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerx Biopharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regenerx Biopharmaceuticals's EV-to-EBITDA falls into.
Regenerx Biopharmaceuticals's current Enterprise Value is $0.24 Mil.
Regenerx Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerx Biopharmaceuticals (RGRX) has a EV-to-EBITDA of -0.18 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regenerx Biopharmaceuticals.
Is Regenerx Biopharmaceuticals' EV-to-EBITDA too high?
Regenerx Biopharmaceuticals' current EV-to-EBITDA is -0.18.
How does Regenerx Biopharmaceuticals' EV-to-EBITDA compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' EV-to-EBITDA of -0.18 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 13.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regenerx Biopharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerx Biopharmaceuticals's current EV-to-EBITDA is -0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current EV-to-EBITDA of -0.18. The current EV-to-EBITDA is -0.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current EV-to-EBITDA is -0.18 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGRX has been successfully added to your 
